JCAR 015

Drug Profile

JCAR 015

Alternative Names: anti-CD19-CD28-zeta CAR transduced T cells - Juno Therapeutics; anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; CD28-modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; JCAR 15; JCAR015

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene
  • 06 Jun 2017 Updated efficacy data from a phase I trial in Acute lymphoblastic leukaemia presented at the American Society for Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Pharmacodynamics and adverse events data from a phase I trial in Acute lymphoblastic leukaemia presented at the 53rd American Society for Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top